(1-甲基-3-吡咯烷基)(3-吡啶基)甲酮 | 125630-26-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (1-甲基-3-吡咯烷基)(3-吡啶基)甲酮
• 英文名称: (R,S)-1-Methyl-3-nicotinoylpyrrolidine
• 英文别名: (1-methylpyrrolidin-3-yl)-pyridin-3-ylmethanone
• CAS: 125630-26-4
• 化学式: C₁₁H₁₄N₂O
• mdl: MFCD01863424
• 分子量: 190.24
• InChiKey: ARYQLVJXQFGHLA-UHFFFAOYSA-N

物化性质

• 沸点：
  313.7±32.0 °C(Predicted)
• 密度：
  1.119±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
  申请人：Solis Herrera Arturo

  公开号：US10639300B2

  公开（公告）日：2020-05-05

  Methods of treating and preventing conditions of a nasal or paranasal mucous membrane are described. The methods include administering a pharmaceutical composition including a nicotinic acetylcholine receptor (nAChR) agonist, such as (S)-(1-methyl-2-pyrrolidinyl)-pyridine, or a pharmaceutically acceptable salt, analog, precursor or derivative thereof. The methods can be used to treat a wide variety of conditions of the nasal or paranasal mucous membrane, such as nasal congestion and nose bleeds.

  本文描述了治疗和预防鼻腔或副鼻腔粘膜疾病的方法。这些方法包括施用药物组合物，其中包括烟碱乙酰胆碱受体（nAChR）激动剂，如(S)-(1-甲基-2-吡咯烷基)-吡啶，或其药学上可接受的盐、类似物、前体或衍生物。这些方法可用于治疗鼻腔或副鼻黏膜的各种疾病，如鼻塞和鼻出血。
• A LIQUID FORMULATION COMPRISING NICOTINE FOR AEROSOL ADMINISTRATION
  申请人：McNeil AB

  公开号：EP3145492A1

  公开（公告）日：2017-03-29
• COMPOSITIONS AND METHODS FOR TREATING PARANASAL MUCOSA DISEASES WITH NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS
  申请人：Solis Herrera, Arturo

  公开号：EP3442583A2

  公开（公告）日：2019-02-20
• LIQUID FORMULATION COMPRISING NICOTINE FOR AEROSOL ADMINISTRATION
  申请人：McNeil AB

  公开号：US20170079319A1

  公开（公告）日：2017-03-23

  In one aspect, the present invention features a method of administering nicotine or a salt thereof to a human, wherein the method includes inhaling an aerosol of a liquid formulation, the liquid formulation comprising: (i) at least 12 percent by weight of water; (ii) at least 70 percent by weight of propylene glycol; and (iii) at least 2 percent by weight of said nicotine or a salt thereof; wherein the liquid formulation includes no more than 5 percent by weight of glycerol and no more than 5 percent by weight of ethanol. The present invention also features an aerosol-generating device and a reservoir for such a device containing such a liquid formulation.
• COMPOSITIONS AND METHODS FOR TREATING NASAL AND PARANASAL MUCOSA DISEASES WITH NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS
  申请人：SOLIS HERRERA Arturo

  公开号：US20190111038A1

  公开（公告）日：2019-04-18

  Methods of treating and preventing conditions of a nasal or paranasal mucous membrane are described. The methods include administering a pharmaceutical composition including a nicotinic acetylcholine receptor (nAChR) agonist, such as (S)-(1-methyl-2-pyrrolidinyl)-pyridine, or a pharmaceutically acceptable salt, analog, precursor or derivative thereof. The methods can be used to treat a wide variety of conditions of the nasal or paranasal mucous membrane, such as nasal congestion and nose bleeds.